Cargando…

Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020

Detalles Bibliográficos
Autores principales:	Cicenas, Jonas, Račienė, Asta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956733/ https://www.ncbi.nlm.nih.gov/pubmed/33668248 http://dx.doi.org/10.3390/cancers13050947

Ejemplares similares

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Molecular Recognition of FDA-Approved Small Molecule Protein Kinase Drugs in Protein Kinases
por: Zhu, Yan, et al.
Publicado: (2022)

Bedaquiline: First FDA-approved tuberculosis drug in 40 years
por: Mahajan, Rajiv
Publicado: (2013)

Prescription Drugs Marketed in the United States Should Be Approved by the FDA
por: Shepherd, Marvin
Publicado: (2003)

Immunotherapy for Breast Cancer: First FDA Approved Regimen
por: Soare, Georgiana R., et al.
Publicado: (2019)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000–2020)
por: Kim, Jeeyun A., et al.
Publicado: (2021)

Kinases and Cancer
por: Cicenas, Jonas, et al.
Publicado: (2018)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2021)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Identification of FDA-approved drugs targeting the Farnesoid X Receptor
por: van de Wiel, Sandra M. W., et al.
Publicado: (2019)

Exploring anti-malarial potential of FDA approved drugs: an in silico approach
por: Ramakrishnan, Gayatri, et al.
Publicado: (2017)

Water Networks in Complexes between Proteins and FDA-Approved Drugs
por: Samways, Marley L., et al.
Publicado: (2022)

Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs
por: Choi, Ha Yeong, et al.
Publicado: (2023)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

The FDA-approved anti-cancer drugs, streptozotocin and floxuridine, reduce the virulence of Staphylococcus aureus
por: Yeo, Won-Sik, et al.
Publicado: (2018)

Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials
por: Nishikawa, Shigeto, et al.
Publicado: (2023)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

A new kind of diabetes medication approved by the FDA: is there hope for obesity?
por: Dhirani, Danisha, et al.
Publicado: (2023)

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
por: Tong, Juliana T. W., et al.
Publicado: (2021)

Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase
por: Zeng, Xiaoyu, et al.
Publicado: (2016)

A systematic analysis of FDA-approved anticancer drugs
por: Sun, Jingchun, et al.
Publicado: (2017)

New FDA approved antibacterial drugs: 2015-2017
por: Andrei, Stefan, et al.
Publicado: (2018)

Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer
por: Kepp, Oliver, et al.
Publicado: (2020)

Comparison of FDA Approved Kinase Targets to Clinical Trial Ones: Insights from Their System Profiles and Drug-Target Interaction Networks
por: Xu, Jingyu, et al.
Publicado: (2016)

Thalamotomy for essential tremor: FDA approval brings brain treatment with FUS to the clinic
por: Fishman, Paul S.
Publicado: (2017)

Impact of Nutrition or FDA-Approved Medicine Repurposing on Metabolic Syndrome and Diabetic Complications
por: Cai, Lu
Publicado: (2023)

Synchrony 2022: Roundtable Discussion on the Pathways and the Challenges of Getting Medications FDA Approved
por: Belfort, Gabriel, et al.
Publicado: (2023)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

In silico Selection and Experimental Validation of FDA-Approved Drugs as Anti-quorum Sensing Agents
por: Mellini, Marta, et al.
Publicado: (2019)

A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles
por: Battah, Basem, et al.
Publicado: (2019)

Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
por: Bibby, Becky A. S., et al.
Publicado: (2021)

A review of FDA approved drugs and their formulations for the treatment of breast cancer
por: Chaurasia, Mohini, et al.
Publicado: (2023)

Identification of FDA-approved Drugs Targeting Breast Cancer Stem Cells Along With Biomarkers of Sensitivity
por: Bhat-Nakshatri, Poornima, et al.
Publicado: (2013)

Identification of natural products and FDA-approved drugs for targeting cancer stem cell (CSC) propagation
por: Bonuccelli, Gloria, et al.
Publicado: (2022)

FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders
por: Lui, Austin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sf58q9fkli3haklrbtrrm5r611